Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers

Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers
Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in a Phase 1 trial for patients with advanced solid tumors, including ovarian cancer. COM701 is an antibody against PVRIG — a new immune checkpoint receptor identified

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *